ASCLETIS
Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China's capital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases.
ASCLETIS
Social Links:
Industry:
Health Care Medical Therapeutics
Founded:
2011-01-01
Address:
Chapel Hill, North Carolina, United States
Country:
United States
Website Url:
http://www.ascletis.com
Total Employee:
251+
Status:
Active
Contact:
1-919-328-0212
Total Funding:
255 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Content Delivery Network Pound Sterling Apple Mobile Web App Capable Japanese Yen Apple Mobile Web App Status Bar Style Baidu Analytics China Ministry Of Public Security
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apogenix
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Autotelic
Autotelic uses therapeutic drug monitoring to enhance the development of therapeutics.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Theraclone Sciences
Theraclone Sciences is a biotech company developing novel therapeutic antibodies for the treatment of infectious diseases and inflammation.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Tasly Pharmaceutical
Tasly Pharmaceutical investment in Series B - Ascletis
Focus Media
Focus Media investment in Series B - Ascletis
QianHai Equity Investment
QianHai Equity Investment investment in Series B - Ascletis
WTT Investment
WTT Investment investment in Series B - Ascletis
Goldman Sachs
Goldman Sachs investment in Series B - Ascletis
C-Bridge Capital
C-Bridge Capital investment in Series B - Ascletis
Goldman Sachs
Goldman Sachs investment in Venture Round - Ascletis
C-Bridge Capital
C-Bridge Capital investment in Series B - Ascletis
Tasly Pharmaceutical
Tasly Pharmaceutical investment in Series B - Ascletis
Pavillion Capital
Pavillion Capital investment in Series B - Ascletis
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-02-11 | Sagimet Biosciences | Ascletis investment in Venture Round - Sagimet Biosciences | 80 M USD |
| 2019-08-05 | Sagimet Biosciences | Ascletis investment in Series E - Sagimet Biosciences | 7 M USD |
| 2019-02-13 | Sagimet Biosciences | Ascletis investment in Series E - Sagimet Biosciences | 18 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-13 | Ascletis Announces Appointment of Mr. John P. Gargiulo, Former North America President and CEO of Daiichi Sankyo, as Chief Business Officer |
Official Site Inspections
http://www.ascletis.com Semrush global rank: 5.18 M Semrush visits lastest month: 1.51 K
- Host name: 47.75.123.183
- IP address: 47.75.123.183
- Location: Central Hong Kong
- Latitude: 22.2909
- Longitude: 114.15
- Timezone: Asia/Hong_Kong
More informations about "Ascletis"
Ascletis Pharma Inc.
Ascletis Pharma Inc. Ascletis was established in 2013, and is listed on the Hong Kong Stock Exchange since 2018 (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of viral diseases, metabolic …See details»
Ascletis Pharma Inc.
我们为员工提供具有竞争力的薪资、福利。如您有意加盟歌礼，请将简历发送至 [email protected]， 我们将尽可能地结合您的专业和公司发展需求，为您提供放飞梦想的舞台。See details»
Ascletis - Crunchbase Company Profile & Funding
Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China's capital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in …See details»
Ascletis - The Org
Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis’ mission is to address unmet medical …See details»
Ascletis Pharma, Inc. - Drug pipelines, Patents, Clinical trials
Explore Ascletis Pharma, Inc. with its drug pipeline, therapeutic area, technology platform, 63 clinical trials, 103 news, and 1 literature, Disease Domain:Infectious Diseases, Neoplasms, …See details»
Ascletis Pharmaceuticals Co.,Ltd. - Drug pipelines, Patents, Clinical ...
Ascletis currently owns the only authorized ritonavir oral tablet in China, which has passed bioequivalence study. About Ascletis Ascletis is an innovative R&D driven biotech listed on the …See details»
Ascletis Pharma Inc.
Ascletis has filed multiple patent applications globally for ASC10 and its use in viral diseases including monkeypox virus infection. Monkeypox virus is an orthopoxvirus that causes a …See details»
Ascletis Pharma Company Description - Stock Analysis
Nov 18, 2024 Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland …See details»
Ascletis Announces Appointment of Mr. John P. Gargiulo, Former …
Jun 13, 2022 Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to …See details»
Ascletis - Funding, Financials, Valuation & Investors - Crunchbase
Ascletis is registered under the ticker OTCPINK:ASCLF . Ascletis is funded by 8 investors. ... Which industries has this organization had the most exits in? Show . Sagimet Biosciences …See details»
Ascletis - Contacts, Employees, Board Members, Advisors & Alumni
Ascletis is a specialty therapeutics company developing therapeutics for the treatment of cancer and infectious diseases.See details»
Ascletis Company Profile - Office Locations, Competitors ... - Craft
Ascletis focuses on building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases.We leverage …See details»
Ascletis Enters the Obesity Drug Space with Announcement of …
Sep 17, 2024 Ascletis received clearance for its Investigational New Drug (IND) applications from the U.S. Food and Drug Administration (FDA) in July 2024 for ASC30 tablets and …See details»
Ascletis Pharma, Inc. (歌礼制药有限公司) - 药物管线_专利_临床试 …
了解Ascletis Pharma, Inc. (歌礼制药有限公司)公司的药物管线，治疗领域，技术平台，以及它的63项临床试验, 533篇新闻和1篇文献，疾病领域:感染，肿瘤，神经系统疾病，免疫系统疾病， …See details»
Ascletis Pharma Inc.
Ascletis is an innovative R&D driven biotech and listed on Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of …See details»
Ascletis Announces Promising Results from a Phase I Study
Nov 7, 2024 Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP …See details»
Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN ...
May 2, 2023 "I am excited about such strong Phase II clinical data," said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis, "As FASN inhibition is a novel mechanism for acne …See details»
Ascletis Pharma Inc.
The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016;131:803–20. [3] 2017 China Cancer Registry Annual …See details»
Ascletis Completes Phase 3 Enrollment for Novel Acne Drug, …
Nov 12, 2024 Ascletis Pharma a terminé le recrutement de 480 patients dans son essai clinique de phase III sur ASC40 (denifanstat), un comprimé oral à prendre une fois par jour pour traiter …See details»
First clinical study using HCV protease inhibitor danoprevir to treat ...
Dec 7, 2020 World Health Organization (WHO) has made the assessment on March 11, 2020 that COVID-19 can be characterized as a pandemic.[1] ... Jinzi J Wu, PhD, one of the …See details»